Implementation of a Novel Adherence Monitoring Strategy in a Phase III, Blinded, Placebo-Controlled, HIV-1 Prevention Clinical Trial.

Marla J Husnik,Elizabeth R Brown,Mark Marzinke,Edward Livant,Thesla Palanee-Phillips,Craig W Hendrix, Flavia Matovu Kiweewa,Gonasagrie Nair,Lydia E Soto-Torres,Katie Schwartz,Sharon L Hillier,Jared M Baeten

Journal of acquired immune deficiency syndromes (1999)（2017）

引用 0|浏览0

暂无评分

摘要

Ongoing drug level testing as a marker of adherence in MTN-020/ASPIRE demonstrates the feasibility of real-time adherence monitoring while maintaining study blinding at the level of participants, sites, and study leadership. This approach is novel for large-scale effectiveness studies for HIV-1 prevention.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要